Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial

Diabetes Care(2025)10.2337/dc24-2425Source: DataRank Database

High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial is a research paper published in Diabetes Care (2025). On theSindex it has a DataRank of 0. It has been cited 22 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access22 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 15.11)OA: bronzeTopics (32)IDs (PubMed, PMC, OpenAlex)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Nils B. Jørgensen ORCID,Bharath Kumar,Ildiko Lingvay ORCID,Anne Sofie Laulund ORCID,John B. Buse ORCID

Live enrichment

PubMed:40279144 PMC:PMC12094194 OpenAlex:https://openalex.org/W4409833976

NIDDK NIH HHS

Grant: P30 DK124723

NCATS NIH HHS

Grant: UM1 TR004406

Novo Nordisk

FWCI

15.11

Citation Percentile

1.0%

Citation Trend

2025

2026

bronzeLicense: https://www.diabetesjournals.org/journals/pages/license

journalhttps://diabetesjournals.org/care/article-pdf/doi/10.2337/dc24-2425/805985/dc242425.pdf

publisherhttps://diabetesjournals.org/care/article-pdf/doi/10.2337/dc24-2425/805985/dc242425.pdf

publisherhttps://diabetesjournals.org/care/article-pdf/48/6/905/805985/dc242425.pdf

journalhttps://doi.org/10.2337/dc24-2425

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40279144

Fields of Study

Diabetes Treatment and ManagementMetabolism, Diabetes, and CancerBariatric Surgery and Outcomes

MeSH Terms

SemaglutideAdultAgedBlood GlucoseDiabetes Mellitus, Type 2Glucagon-Like PeptidesFemaleGlycated HemoglobinHumansHypoglycemic AgentsMaleMetforminMiddle AgedObesityOverweightGlucagon-Like Peptide 1

Keywords

MedicineSemaglutideOverweightType 2 diabetesPlaceboRandomized controlled trialObesityDiabetes mellitusInternal medicinePhysical therapyEndocrinologyAlternative medicineLiraglutide